Resistance to Proteasome Inhibitors in Cancer

Molecular Mechanisms and Strategies to Overcome Resistance

Nonfiction, Health & Well Being, Medical, Specialties, Oncology, Medical Science, Pharmacology
Cover of the book Resistance to Proteasome Inhibitors in Cancer by , Springer International Publishing
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9783319067520
Publisher: Springer International Publishing Publication: September 16, 2014
Imprint: Springer Language: English
Author:
ISBN: 9783319067520
Publisher: Springer International Publishing
Publication: September 16, 2014
Imprint: Springer
Language: English

The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases, histone deacetylases, oxidative stress and proteotoxic stress pathways and pharmacogenomic signature profiling) in resistant cancer cells. The mechanisms of action and resistance of proteasome inhibitors, such as bortezomib and carfilzomib in human cancers, including multiple myeloma, mantle cell lymphoma, acute leukemia, and solid tumors are explored in depth in this volume.

This timely volume unveils the most current discoveries of the mechanisms behind proteasome inhibitor resistance, which will help illuminate the future of cancer therapies.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases, histone deacetylases, oxidative stress and proteotoxic stress pathways and pharmacogenomic signature profiling) in resistant cancer cells. The mechanisms of action and resistance of proteasome inhibitors, such as bortezomib and carfilzomib in human cancers, including multiple myeloma, mantle cell lymphoma, acute leukemia, and solid tumors are explored in depth in this volume.

This timely volume unveils the most current discoveries of the mechanisms behind proteasome inhibitor resistance, which will help illuminate the future of cancer therapies.

More books from Springer International Publishing

Cover of the book De Sitter Projective Relativity by
Cover of the book The Floating Strip Micromegas Detector by
Cover of the book Neoplastic Diseases of the Blood by
Cover of the book Sex and Gender Differences in Infection and Treatments for Infectious Diseases by
Cover of the book ENT by
Cover of the book Islamic Finance by
Cover of the book Integrated Community-Managed Development by
Cover of the book Contradictions, from Consistency to Inconsistency by
Cover of the book Weird Astronomical Theories of the Solar System and Beyond by
Cover of the book The Power of Philosophy by
Cover of the book The Science and Practice of Resilience by
Cover of the book Cybernetics and Automation Control Theory Methods in Intelligent Algorithms by
Cover of the book Formation, Evolution, and Dynamics of Young Solar Systems by
Cover of the book Modelling and Simulation of Diffusive Processes by
Cover of the book Atlas of Head and Neck Endocrine Disorders by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy